actoferrin in the treatment of Long COVID

Recruiting

Conditions: ong COVID

Registration Number: NL-OMON21473

Lead Sponsor: Stichting O&O Franciscus Gasthuis & Vlietland

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 72

Inclusion Criteria

Persistent or newly developed long COVID symptoms at least 12 weeks post-primary SARS-CoV-2 infection
-Patients with a positive COVID-19 RT-PCR- or antibody test not older than 9 months
-Adult patients with age >18 years

Exclusion Criteria

-Patients admitted to the ICU (COVID-19-related)
-COVID-19-related cardiac or pulmonary tissue damage
-Acute infection or current systemic immunological disorders
-Oral and/or inhaled use of corticosteroids or use of other immune-modulatory medication
-Current psychiatric disorders
-Communication difficulties
-Pregnant or lactating women
-Age >70 years
-Patients with milk allergy or a known or suspected allergy or any contraindications to lactoferrin or microcrystalline cellulose (lactoferrin can be used by individuals with lactose intolerance)

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-Do fatigue symptoms diminish faster with the use of lactoferrin combined with usual care compared to usual care solely?

Secondary Outcome Measures

Name	Time	Method
-Do anxiety and depressive symptoms diminish (faster) with the use of lactoferrin?<br>-Does the use of lactoferrin (faster) improve cognitive function?<br>-Does muscle strength recover (faster) with the use of lactoferrin?<br>-Does the use of lactoferrin have an effect on inflammatory blood parameters? <br>-How do changes in subjective health parameters correlate with circulating biomarkers?<br>